PURPOSE: Breast cancer is a heterogeneous disease, with at least five intrinsic subtypes defined by molecular characteristics. Tumors that express the estrogen receptor (ER+) have better outcomes than ER- tumors, due in part to the success of hormonal therapies that target ER+ tumors. The incidence of ER- breast cancer, and the subset of ER- cancers that are basal-like, is about twice as high among African American (AA) women as among US women of European descent (EA). This disparity appears to explain, in part, the disproportionately high mortality from breast cancer that occurs in AA women. Epidemiologic research on breast cancer in AA women lags behind research in EA women. Here, we review differences in the etiology of breast cancer subtypes among AA women and describe a new consortium of ongoing studies of breast cancer in AA women. METHODS: We combined samples and data from four large epidemiologic studies of breast cancer in AA women, two cohort and two case-control, creating the African American Breast Cancer Epidemiology and Risk consortium. Tumor tissue is obtained and stored in tissue microarrays, with assays of molecular markers carried out at a pathology core. Genotyping, carried out centrally, includes a whole exome SNP array and over 180,000 custom SNPs for fine-mapping of genome-wide association studies loci and candidate pathways. RESULTS: To date, questionnaire data from 5,739 breast cancer cases and 14,273 controls have been harmonized. Genotyping of the first 3,200 cases and 3,700 controls is underway, with a total of 6,000 each expected by the end of the study period. CONCLUSIONS: The new consortium will likely have sufficient statistical power to assess potential risk factors, both genetic and non-genetic, in relation to specific subtypes of breast cancer in AA women.
PURPOSE:Breast cancer is a heterogeneous disease, with at least five intrinsic subtypes defined by molecular characteristics. Tumors that express the estrogen receptor (ER+) have better outcomes than ER- tumors, due in part to the success of hormonal therapies that target ER+tumors. The incidence of ER- breast cancer, and the subset of ER- cancers that are basal-like, is about twice as high among African American (AA) women as among US women of European descent (EA). This disparity appears to explain, in part, the disproportionately high mortality from breast cancer that occurs in AA women. Epidemiologic research on breast cancer in AA women lags behind research in EA women. Here, we review differences in the etiology of breast cancer subtypes among AA women and describe a new consortium of ongoing studies of breast cancer in AA women. METHODS: We combined samples and data from four large epidemiologic studies of breast cancer in AA women, two cohort and two case-control, creating the African American Breast Cancer Epidemiology and Risk consortium. Tumor tissue is obtained and stored in tissue microarrays, with assays of molecular markers carried out at a pathology core. Genotyping, carried out centrally, includes a whole exome SNP array and over 180,000 custom SNPs for fine-mapping of genome-wide association studies loci and candidate pathways. RESULTS: To date, questionnaire data from 5,739 breast cancer cases and 14,273 controls have been harmonized. Genotyping of the first 3,200 cases and 3,700 controls is underway, with a total of 6,000 each expected by the end of the study period. CONCLUSIONS: The new consortium will likely have sufficient statistical power to assess potential risk factors, both genetic and non-genetic, in relation to specific subtypes of breast cancer in AA women.
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Dezheng Huo; Yonglan Zheng; Temidayo O Ogundiran; Clement Adebamowo; Katherine L Nathanson; Susan M Domchek; Timothy R Rebbeck; Michael S Simon; Esther M John; Anselm Hennis; Barbara Nemesure; Suh-Yuh Wu; M Cristina Leske; Stefan Ambs; Qun Niu; Jing Zhang; Nancy J Cox; Olufunmilayo I Olopade Journal: Carcinogenesis Date: 2012-02-22 Impact factor: 4.944
Authors: Wei Zheng; Qiuyin Cai; Lisa B Signorello; Jirong Long; Margaret K Hargreaves; Sandra L Deming; Guoliang Li; Chun Li; Yong Cui; William J Blot Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-09-29 Impact factor: 4.254
Authors: Shanna Nesby-O'Dell; Kelley S Scanlon; Mary E Cogswell; Cathleen Gillespie; Bruce W Hollis; Anne C Looker; Chris Allen; Cindy Doughertly; Elaine W Gunter; Barbara A Bowman Journal: Am J Clin Nutr Date: 2002-07 Impact factor: 7.045
Authors: Christine B Ambrosone; Gregory L Ciupak; Elisa V Bandera; Lina Jandorf; Dana H Bovbjerg; Gary Zirpoli; Karen Pawlish; James Godbold; Helena Furberg; Anne Fatone; Heiddis Valdimarsdottir; Song Yao; Yulin Li; Helena Hwang; Warren Davis; Michelle Roberts; Lara Sucheston; Kitaw Demissie; Kandace L Amend; Paul Tartter; James Reilly; Benjamin W Pace; Thomas Rohan; Joseph Sparano; George Raptis; Maria Castaldi; Alison Estabrook; Sheldon Feldman; Christina Weltz; Margaret Kemeny Journal: J Oncol Date: 2009-10-25 Impact factor: 4.375
Authors: Song Yao; Stephen A Haddad; Qiang Hu; Song Liu; Kathryn L Lunetta; Edward A Ruiz-Narvaez; Chi-Chen Hong; Qianqian Zhu; Lara Sucheston-Campbell; Ting-Yuan David Cheng; Jeannette T Bensen; Candace S Johnson; Donald L Trump; Christopher A Haiman; Andrew F Olshan; Julie R Palmer; Christine B Ambrosone Journal: Int J Cancer Date: 2015-12-28 Impact factor: 7.396
Authors: Altovise T Ewing; Nnenna Kalu; Gloria Cain; Lori H Erby; Luisel J Ricks-Santi; Eva Tetteyfio-Kidd Telemaque; Denise M Scott Journal: J Community Genet Date: 2019-03-14
Authors: Song Yao; Chi-Chen Hong; Elisa V Bandera; Qianqian Zhu; Song Liu; Ting-Yuan David Cheng; Gary Zirpoli; Stephen A Haddad; Kathryn L Lunetta; Edward A Ruiz-Narvaez; Susan E McCann; Melissa A Troester; Lynn Rosenberg; Julie R Palmer; Andrew F Olshan; Christine B Ambrosone Journal: Am J Clin Nutr Date: 2017-04-19 Impact factor: 7.045
Authors: Lindsay A Williams; Andrew F Olshan; Chi-Chen Hong; Elisa V Bandera; Lynn Rosenberg; Ting-Yuan David Cheng; Kathryn L Lunetta; Susan E McCann; Charles Poole; Laurence N Kolonel; Julie R Palmer; Christine B Ambrosone; Melissa A Troester Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-04-18 Impact factor: 4.254
Authors: Allyson C Espinal; Matthew F Buas; Dan Wang; David Ting-Yuan Cheng; Lara Sucheston-Campbell; Qiang Hu; Li Yan; Rochelle Payne-Ondracek; Eduardo Cortes; Li Tang; Zhihong Gong; Gary Zirpoli; Thaer Khoury; Song Yao; Angela Omilian; Kitaw Demissie; Elisa V Bandera; Song Liu; Christine B Ambrosone; Michael J Higgins Journal: Breast Cancer Res Treat Date: 2017-07-29 Impact factor: 4.872
Authors: Song-Yi Park; Julie R Palmer; Lynn Rosenberg; Christopher A Haiman; Elisa V Bandera; Traci N Bethea; Melissa A Troester; Emma Viscidi; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone Journal: Carcinogenesis Date: 2016-04-07 Impact factor: 4.944
Authors: Lynn Chollet-Hinton; Andrew F Olshan; Hazel B Nichols; Carey K Anders; Jennifer L Lund; Emma H Allott; Traci N Bethea; Chi-Chen Hong; Stephanie M Cohen; Thaer Khoury; Gary R Zirpoli; Virginia F Borges; Lynn A Rosenberg; Elisa V Bandera; Christine B Ambrosone; Julie R Palmer; Melissa A Troester Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-09-13 Impact factor: 4.254
Authors: Lynn Rosenberg; Traci N Bethea; Emma Viscidi; Chi-Chen Hong; Melissa A Troester; Elisa V Bandera; Christopher A Haiman; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer Journal: J Natl Cancer Inst Date: 2015-11-26 Impact factor: 13.506
Authors: Ting-Yuan David Cheng; Christine B Ambrosone; Chi-Chen Hong; Kathryn L Lunetta; Song Liu; Qiang Hu; Song Yao; Lara Sucheston-Campbell; Elisa V Bandera; Edward A Ruiz-Narváez; Stephen Haddad; Melissa A Troester; Christopher A Haiman; Jeannette T Bensen; Andrew F Olshan; Julie R Palmer; Lynn Rosenberg Journal: Carcinogenesis Date: 2015-11-16 Impact factor: 4.944